FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, and significantly reduced...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Children | Corticosteroid Therapy | Dermatitis | Dermatology | Drugs & Pharmacology | Skin